Figure 6
Figure 6. Requirements for VEGFR-2 and VEGFR-3 in Notch inhibition-induced lymphatic sprouting in vivo. (A-F) Lymphatic vessels stained by VEGFR-3 2 weeks after transduction of mouse ears with the indicated rAAVs. (G-M) Close-up views of panels A through F. (N) Quantification of the ear lymphatic vessel branchpoints in mice transduced with the indicated rAAVs. R1-Fc indicates VEGFR-1-Fc; and R3-Fc, VEGFR-3(domain1-3)-Fc. Ctrl-Fc indicates VEGFR-3(domain 4-7)-Fc, used as a negative control. Scale bars, 100 μm. Results represent means ± SEM summarized from 2 independent experiments with n = 4-8 per group per experiment; *P < .05; ***P < .001 compared with the first bar in panel N.

Requirements for VEGFR-2 and VEGFR-3 in Notch inhibition-induced lymphatic sprouting in vivo. (A-F) Lymphatic vessels stained by VEGFR-3 2 weeks after transduction of mouse ears with the indicated rAAVs. (G-M) Close-up views of panels A through F. (N) Quantification of the ear lymphatic vessel branchpoints in mice transduced with the indicated rAAVs. R1-Fc indicates VEGFR-1-Fc; and R3-Fc, VEGFR-3(domain1-3)-Fc. Ctrl-Fc indicates VEGFR-3(domain 4-7)-Fc, used as a negative control. Scale bars, 100 μm. Results represent means ± SEM summarized from 2 independent experiments with n = 4-8 per group per experiment; *P < .05; ***P < .001 compared with the first bar in panel N.

Close Modal

or Create an Account

Close Modal
Close Modal